Posted by: Bert Copple | May 19, 2011

New, Better Alzheimer’s Treatment in Ten Years?

A new Alzheimer’s Society research program could open the doors tor new and more effective treatments for dementia within the next ten years. The program, called Drug Discovery, hopes to develop treatments that not only delay the onset of dementia, but also provide benefits for five times longer than current dementia drugs.

Alzheimer’s Society Ambassador and Oscar winning writer Julian Fellowes, Lord Fellowes of West Stafford, will today host a launch reception at the House of Lords. He will be joined by fellow ambassador and long-term supporter Fiona Phillips. The stars are stepping out to support the novel and exciting dementia research program which offers hope to millions of people.

“This programme is more than a ray of hope for 750, 000 people with dementia, their carers and families,” said Fellowes. “At a time when the number of people with this condition is rising, it is wonderful to see the Alzheimer’s Society striding ahead in the race to find a cure and new treatments. In short, it is a tremendous opportunity, and something really to celebrate.”

Fiona Phillips also commented on the new program, saying, “I know from caring for both my mum and my dad the devastating impact that dementia can have on the person living with the condition and their families. Investing in treatment development today has to be a priority if we are to change this picture.  That is why I am so happy to offer my support to this major project which has the potential to transform the lives of so many.”

Drug Discovery will be testing treatments that are already available and licensed for other conditions. These treatments have additional actions that may be successful in treating the changes that occur in the brain in an Alzheimer’s patient. These six chosen drugs for trial are being fast-tracked for exploration in scientific studies. Clinical trials of the drugs will soon follow to test the benefits towards dementia and Alzheimer’s.

The reason that the drugs will be tested so quickly and cost-effectively is because the drugs are already available and developed; further research exploration is the main cost of this endeavor, and it is expected to total at £15 million. Compared to preparing a new drug from scratch, which would cost one billion US dollars (approx £612.7million GBP) and take 20 years to complete, this is an astounding amount of time and money well saved.

This new research could prove to be the next step in taking on Alzheimer’s disease and dementia. Until then we must continue to take the initiative and provide extra care for dementia patients, and there is no company better at that than Home Instead Senior Care.

Home Instead is not only the leading in-home care company in the world, but they also have a world-renowned Alzheimer’s Care Program. If you have a loved one who is suffering from dementia or Alzheimer’s, or if you have noticed signs of dementia, please do not hesitate to call and get the extra care they may need, as well as peace of mind for yourself.

Home Instead Senior Care will provide outstanding CAREGivers to help your loved one with personal care, incidental travel, companionship, medication reminders, light housekeeping, and even meal preparation. To learn more, call 248-203-2273 or visit www.homeinstead.com. Home Instead Senior Care is the world’s trusted source of in-home non-commercial personal care and companionship for seniors. Each franchise is independently owned and operated. And remember, to us, it’s personal.

SOURCE: MatureTimes.co.uk

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Categories

%d bloggers like this: